Radiographic Lung Volumes Predict Progression to COPD in Smokers with Preserved Spirometry in SPIROMICS

COPD

Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort

Ann Am Thorac Soc.

Martinez CH, Murray S, Barr RG, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ, Curtis JL, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Krishnan JA, Lazarus SC, Leidy NK, O'Neal W, Martinez FJ, Paine R 3rd, Rennard SI, Tashkin DP, Woodruff PG, Han MK; Subpopulations and Intermediate Outcome Measures in COPD Study Investigators

doi: 10.1513/

RECOMMENDED

COPD

Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS)

Respir Res.

Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD Jr, Lee CH, Barr RG, Bleecker E, Cooper CB, Couper D, Han ML, Hansel NN, Kanner RE, Kazerooni EA, Kleerup EAC, Martinez FJ, O'Neal W, Paine R 3rd, Rennard SI, Smith BM, Woodruff PG, Lin CL

doi: 10.1186/s12931-

RECOMMENDED

Lung Cancer

Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients

★ 2 Recommended by Dr Martin Frey, Faculty Member

Lung Cancer.

Tessema M, Tassew DD, Yingling CM, Do K, Picchi MA, Wu G, Petersen H, Randell S, Lin Y, Belinsky SA, Tesfaigzi Y

doi: 10.1016/j.lungcan.2020.05.017.

COMMENTED

COPD

Associations between 25-hydroxy-vitamin D levels, lung function, and exacerbation outcomes in COPD: An analysis of the SPIROMICS cohort

★ 3 Recommended and commented by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

Chest.

Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, Barr RG, Krishnan JA, Cooper C, Labaki WW, Ortega VE, Wells JM, Criner GJ, Woodruff PG, Bowler RP, Pirozzi CS, Hansel NN, Wise R, Brown TT, Drummond MB, SPIROMICS Investigators

doi: 10.1016/j.chest.2019.11.047.

RECOMMENDED

COPDCoughEmphysema

Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Respir Res

Kellerer C, Jörres RA, Schneider A, Alter P, Kauczor HU, Jobst B, Biederer J, Bals R, Watz H, Behr J, Kauffmann-Guerrero D, Lutter J, Hapfelmeier A, Magnussen H, Trudzinski FC, Welte T, Vogelmeier CF, Kahnert K

doi: 10.1186/s12931-021-01837-2

Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study

Pulm Pharmacol Ther.

Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, Cazzola M

doi: 10.1016/j.pupt.2017.12.010.

RECOMMENDED

COPD

Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD

★ 3 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Thorax.

Balata H, Harvey J, Barber PV, Colligan D, Duerden R, Elton P, Evison M, Greaves M, Howells J, Irion K, Karunaratne D, Mellor S, Newton T, Sawyer R, Sharman A, Smith E, Taylor B, Taylor S, Tonge J, Walsham A, Whittaker J, Vestbo J, Booton R, Crosbie PA

doi: 10.1136/thoraxjnl-2019-213584.

RECOMMENDED

COPDEmphysema

Significance of FEV₃/FEV₆ in recognition of early airway disease in smokers at risk of development of COPD: Analysis of the SPIROMICS cohort

★ 1 Recommended by Dr Martin Frey, Faculty Member

Chest

Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R 3rd, Woodruff PG, Han MK, Martinez FJ, Barr RG, Wells JM, Ortega VE, Hoffman EA, Kim V, Drummond MB, Bowler RP, Curtis JL, Cooper CB, Tashkin DP, Barjaktarevic IZ

doi: 10.1016/j.chest.2021.10.046

Interstitial Lung Disease

Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis

Arthritis Rheumatol.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S

doi: 10.1002/art.41020.

Related content

Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort

Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS)

Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients

Associations between 25-hydroxy-vitamin D levels, lung function, and exacerbation outcomes in COPD: An analysis of the SPIROMICS cohort

Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET

Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study

Spirometry performed as part of the Manchester community-based lung cancer screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD

Significance of FEV3/FEV6 in recognition of early airway disease in smokers at risk of development of COPD: Analysis of the SPIROMICS cohort

Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis

Significance of FEV₃/FEV₆ in recognition of early airway disease in smokers at risk of development of COPD: Analysis of the SPIROMICS cohort